Polaryx Therapeutics (PLYX) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about PLYX filings

Are insiders buying or selling Polaryx Therapeutics, Inc. Common Stock (PLYX) stock?

Neither. Polaryx Therapeutics, Inc. Common Stock (PLYX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded PLYX recently?

None. No member of Congress disclosed a PLYX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this PLYX smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

5 funds hold a position and insiders have been net buying.

Questions about PLYX filings

Are insiders buying or selling Polaryx Therapeutics, Inc. Common Stock (PLYX) stock?

Neither. Polaryx Therapeutics, Inc. Common Stock (PLYX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded PLYX recently?

None. No member of Congress disclosed a PLYX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this PLYX smart-money data?

Insiders

What insiders are doing

1 trade · 6 mo

Buys (1)

YA
Yang Alex Keun Mo
Chief Executive Officer, 10% · Held by Mstone Partners Healthcare Limited · May 28
$360K
private deal
Signals like this: n=2459, 52% finished lower at D15, median -0.4% vs SPY +0.2%

Unlock everything for $29/month

Unlock for $29/month

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

The latest quarter is still settling.

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 12, 2026	Not on file	No estimate	Not on file	Not on file
Jun 30, 2026Reported Aug 13, 2026	-$0.03est. -$0.05	+$0.02beat	$0.00Alpha Vantage	No year-ago quarter
Mar 31, 2026Reported May 15, 2026	-$0.05est. -$0.02	-$0.03miss	$0.00Alpha Vantage	No year-ago quarter
Dec 31, 2025Reported Jan 27, 2026	-$0.16est. -$0.02	-$0.14miss	$0.00Alpha Vantage	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.83
High: $1.94
Low: $1.80
Prev close: $1.80
52-wk high: $48.91
52-wk low: $1.69
Mkt cap: $93.7M
ROE: -96.6%
P/B: 8.8x
Profit margin: +0.0%
Op margin: +0.0%

Sep 2025 to Jun 2026

What it sold, what it cost, what was left.

RevenueProfit

Sep 2025Dec 2025Mar 2026Jun 2026

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
What it spent
Research and development	$514.0K	$560.0K	$679.0K	$719.0K
Sales and adminSelling, general and administrative	$460.0K	$351.0K	$1.3M	$661.0K
Total operating expenses	$974.0K	$911.0K	$2.0M	$1.4M
What was left
Operating profitOperating income	-$974.0K	-$911.0K	-$2.0M	-$1.4M
Profit before tax	-$1.4M	-$1.5M	-$2.5M	-$1.4M
Net profitNet income	-$1.4M	-$1.5M	-$2.5M	-$1.4M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$1.4M	-$1.5M	-$2.5M	-$1.4M

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

35 / 100

RSI 14

51balanced

20D volatility

51%annualized

52-week range

$1.92

$1.69$48.91

20D support

$1.69recent floor

20D resistance

$2.05recent ceiling

Returns

5D +9.7%20D -4.5%60D -26.2%

Price vs moving averages

SMA20 +3.1%SMA50 -2.9%

Volume pace

0.70xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 12, 2026

Not on file

No estimate

Not on file

Jun 30, 2026Aug 13, 2026

-$0.03est. -$0.05

+$0.02

$0.00Alpha Vantage

No year-ago quarter

Mar 31, 2026May 15, 2026

-$0.05est. -$0.02

-$0.03

$0.00Alpha Vantage

No year-ago quarter

Dec 31, 2025Jan 27, 2026

-$0.16est. -$0.02

-$0.14

$0.00Alpha Vantage

No year-ago quarter

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
What it spent
Research and development	$514.0K	$560.0K	$679.0K	$719.0K
Sales and adminSelling, general and administrative	$460.0K	$351.0K	$1.3M	$661.0K
Total operating expenses	$974.0K	$911.0K	$2.0M	$1.4M
What was left
Operating profitOperating income	-$974.0K	-$911.0K	-$2.0M	-$1.4M
Profit before tax	-$1.4M	-$1.5M	-$2.5M	-$1.4M
Net profitNet income	-$1.4M	-$1.5M	-$2.5M	-$1.4M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$1.4M	-$1.5M	-$2.5M	-$1.4M

USD

Sep 2025

Dec 2025

Mar 2026

Jun 2026

What came in

RevenueTotal revenue

What it spent

Research and development

$514.0K

$560.0K

$679.0K

$719.0K

Sales and adminSelling, general and administrative

$460.0K

$351.0K

$1.3M

$661.0K

Total operating expenses

$974.0K

$911.0K

$2.0M

$1.4M

What was left

Operating profitOperating income

-$974.0K

-$911.0K

-$2.0M

-$1.4M

Profit before tax

-$1.4M

-$1.5M

-$2.5M

-$1.4M

Net profitNet income

-$1.4M

-$1.5M

-$2.5M

-$1.4M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$1.4M

-$1.5M

-$2.5M

-$1.4M

Polaryx Therapeutics, Inc. Common Stock

Smart money at a glance

What do analysts expect?

Questions about PLYX filings

Questions about PLYX filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Polaryx Therapeutics, Inc. Common Stock

Smart money at a glance

What do analysts expect?

Questions about PLYX filings

Questions about PLYX filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Polaryx Therapeutics, Inc. Common Stock

Overview

Questions about PLYX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Polaryx Therapeutics, Inc. Common Stock

Overview

Questions about PLYX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.